AptarGroup (AGT) AI Stock Analysis

0 Followers

AptarGroup

(Frankfurt:AGT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Pharma pipeline and recurring revenueA broad development pipeline across multiple drug-delivery technologies supports future program wins and customer retention. The stated high proportion of repeat growing revenue adds durability, while exposure to biologics, GLP-1 medicines and other therapies can sustain demand beyond individual product cycles.

Negative Factors

Sustained margin and earnings pressureThe decline in profitability shows that recent revenue growth is not fully translating into earnings expansion. Lower margins can constrain reinvestment and reduce operating leverage, particularly if unfavorable product mix, cost pressures or weaker segment execution persist through the coming quarters.

AptarGroup (AGT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.05B
Dividend Yield: 1.42%
Average Volume (3M): 170
Price to Earnings (P/E): 34.2
Beta (1Y): 0.51
Revenue Growth: 3.71%
EPS Growth: -37.29%
Country: Germany
Employees: 14,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

AptarGroup Business Overview & Revenue Model

Company Description

AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (includi...

AptarGroup Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:4.33%|Next Earnings Date:Feb 17, 2027

Earnings Call SentimentPositive

The call was predominantly positive. Aptar reported 5% core sales growth across all three segments, strong underlying Pharma growth, robust pipeline activity, solid cash generation and a positive fourth-quarter outlook. However, profitability declined year-over-year, Beauty's North American operations remain a significant execution challenge, emergency medicine growth is expected to normalize at a lower rate, and the company recorded a substantial Russian subsidiary deconsolidation charge. Management expressed confidence in the portfolio and long-term opportunities while acknowledging that operational improvements, particularly in Beauty, will take time.

Positive Updates

Broad-Based Sales Growth Across All Segments

Reported sales increased 6% to just over $1 billion, while core sales increased 5% year-over-year across all three segments, driven by segment growth and pass-throughs of higher input costs.

Negative Updates

Russian Subsidiary Deconsolidation Charge

Aptar deconsolidated its Russian subsidiary effective September 21, 2026, after it came under administrative control. The company recorded a combined charge of $61.2 million before tax and $60.4 million after tax, or $0.94 per diluted share, including a $58 million loss on deconsolidation and approximately $30 million of cash held by the subsidiary, along with receivable reserves and legal costs.

Company Guidance

For Q4 2026, Aptar anticipates adjusted earnings per share of $1.39 to $1.47, with the midpoint reflecting expected growth of 17% from prior year Q4, including comparable exchange rates; Vanessa also described the midpoint as about 14% year-over-year growth and about 17% on a like-for-like currency basis. The outlook assumes an effective tax rate range of 17.5% to 19.5% and a euro to U.S. dollar exchange rate of 1.12. For the full year 2026, capital investments are expected to be in the range of $260 million to $280 million and depreciation and amortization expense between $310 million and $320 million. Emergency medicine sales are expected to decrease by approximately $65 million for the full year 2026, with the destocking expected to lap in the fourth quarter, while naloxone is expected to have GDP, GDP plus type growth moving forward. Pharma is expected to finish the year driven by continued growth, with margins expected to improve year-over-year, and its long-term target remains the 7% and 11% corridor; Injectables is expected to be in the high single digit and low double digits. The long-term effective tax rate is expected to be in the 21% to 23% range.

AptarGroup Risk Analysis

AptarGroup disclosed 28 risk factors in its most recent earnings report. AptarGroup reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

AptarGroup Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AGT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	78Outperform	$28.41B	45.37	21.08%	0.22%	12.60%	32.05%
AVTR	66Neutral	$10.58B	31.11	5.96%	―	0.92%	―
BDX	63Neutral	$54.10B	59.69	3.79%	2.01%	-2.56%	-40.38%
STVN	59Neutral	$5.39B	26.12	8.94%	0.44%	12.00%	4.92%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	47Neutral	$12.53B	-18.47	-11.62%	0.16%	5.33%	-164.67%

* Healthcare Sector Average

Performance Comparison

DE:AGT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AGT	AptarGroup, Inc.	118.00	19.03	19.22%
BAX	Baxter International Inc	25.49	7.54	42.05%
BDX	Becton, Dickinson and Co	198.17	62.17	45.71%
WST	West Pharmaceutical Services, Inc.	406.99	132.51	48.28%
AVTR	Avantor	15.59	4.27	37.72%
STVN	Stevanato Group Spa	14.10	-10.22	-42.03%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AptarGroup AI Stock Analysis